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 INTRODUCTION
This chapter discusses the considerations and techniques
for  anaesthetizing  animals  with  neurological  disease.
The chapter will cover intracranial disease, spinal disease
and  NM  disease.  A  thorough  understanding  of  the
pathophysiology of diseases affecting these regions of the
nervous system is essential to select the most appropriate
anaesthetic technique and drug combination.
INTRACRANIAL DISEASE
Considerations
The main aim of anaesthesia in animals with intracranial
disease is to preserve neuronal function. Normal neuro-
nal function depends on maintaining adequate CBF. 
CBF regulation is complex and will not be described
in detail in this chapter (for more details see Further
reading). Put simply, CBF is maintained if CPP is main-
tained.  The  CPP  represents  the  difference  between
MAP and ICP. The considerations for maintaining CBF
and minimizing neuronal injury during anaesthesia will
be discussed with reference to the stages of the anaes-
thetic procedure (stabilization, induction, maintenance
and recovery from anaesthesia). This is summarized in
Table 99 (p. 537). 
Stabilization prior to anaesthesia
Any patient with increased ICP (404), regardless of the
cause, requires stabilization before considering anaes-
thesia or sedation for further diagnostics. 
Correction of hypoxaemia, hypercapnia and poor
perfusion are the most important strategies for reducing
ICP  and  stabilizing  the  patient  prior  to  anaesthesia.
(For specific details on supporting the respiratory and
cardiovascular systems see Chapter 2.) 
Specific management of increased ICP is indicated if
deterioration of neurological status occurs rapidly or
continues despite normal oxygenation, ventilation and
perfusion.  (For  management  of  increased  ICP  see
Chapter 20.)
Sedation 
In animals with clinical signs of intracranial disease, 
the performance of procedures under heavy sedation is 
generally avoided. Heavy sedation may lead to excessive
depression of cardiovascular and respiratory function,
535
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  404 Animals with intracranial disease are at risk of
increased ICP and subsequent brain herniation (as shown
on this sagittal T2-weighted MR image [arrow]) if
appropriate stabilization is not performed prior to
anaesthesia. (Photo courtesy Victoria Johnson)
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In addition, heavy sedation may interfere with accurate
assessment of the neurological status of the animal and
delay initiation of appropriate therapy. 
In these cases, anaesthesia performed carefully with 
a good understanding of how to minimize detrimental
effects is preferable, as this allows protection of the
airway and control of ventilation. In addition, many
anaesthetic agents, such as propofol and barbiturates,
have the added benefit of reducing cerebral metabolic
rate, which helps reduce neurological injury.
Premedication 
The aims of premedication are to:
•R e d u c e   s t r e s s   a n d   a n x i e t y .  
•D e c r e a s e   t h e   a m o u n t   o f   a n a e s t h e t i c   i n d u c t i o n   a n d
maintenance agents required. 
•P r o v i d e   a n a l g e s i a .
Agents used for premedication should have minimal
effects on cerebral perfusion and ICP. The advantages
and disadvantages of different agents in animals with
intracranial disease are detailed in Table  100  (p. 539).
Drugs such as acepromazine and medetomidine are best
avoided in animals with intracranial disease.
Opioids provide analgesia and varying degrees of
sedation without affecting cerebral perfusion or ICP.
Adverse effects associated with a decrease in heart rate
and respiratory depression can be avoided by using con-
servative doses. Morphine administration is best avoided
in patients with high ICP given its significant potential
for causing vomiting (and transient increases inICP).
Benzodiazepines may be useful as anxiolytics in criti-
cally ill animals. These agents should be used cautiously
in animals with mild disease/minimal decreases in men-
tation, as the effects can be unreliable and excitement,
dysphoria and disinhibition can occur.
Phenobarbital is the drug most often used to control
seizures. The authors have found that the administration
of phenobarbital at 2–3 mg/kg intramuscularly can be a
useful premedicant in anxious dogs when used in con-
junction with an opioid 30 minutes prior to induction of
anaesthesia.
Adjustment of dose rates of sedative and
anaesthetic agents 
In  animals  with  intracranial  disease,  damage  to  the
blood–brain barrier and concurrent CNS depression due
to the neurological injury will serve to exacerbate the
effects of a given dose of anaesthetic or analgesic agent.
As a result, the doses used in these patients should be
lower than those used in healthy patients. As the agents
have a rapid onset and short duration of action, the dose
rate can be adjusted incrementally (i.e. titrated to effect)
until  the  desired  analgesic  effect  is  achieved,  while 
minimizing side-effects. 
Induction of anaesthesia 
A smooth and high-quality induction of anaesthesia is
essential. Minimizing stress and struggling and main-
taining oxygenation and ventilation during induction of
anaesthesia is necessary to prevent adverse effects on the
CNS. The induction of anaesthesia using intravenous
agents minimizes struggling and allows rapid control of
the airway.
Pre-oxygenation is performed by mask, if tolerated,
or by flow-by (406) for 5–10 minutes prior to induction
to  minimize  hypoxaemia  during  and  immediately
following induction of anaesthesia.
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  405 Heavy sedation, as seen in this Bull Terrier, is
generally avoided in patients with intracranial disease, due
to the risk of excessive cardiovascular and respiratory
depression. EMERGENCY NEUROANAESTHESIA 537
CONSIDERATION MANAGEMENT
Maintain adequate CPP 
(CPP = MAP – ICP)
Maintain haemodynamic stability
Ensure adequate ventilation and 
normocapnia (PaCO2 35–40 mmHg)
Maintain adequate oxygenation
Decrease CMR
Ensure adequate venous drainage
MAP = mean arterial blood pressure; ICP = intracranial pressure; CBF = cerebral blood flow; CMR = cerebral metabolic rate;
PaCO2 = arterial carbon dioxide partial pressure.
Maintain MAP between 80 mmHg and 100 mmHg. Maintain normal
circulating blood volume. Minimize depressant effects of anaesthetic agents
on cardiovascular function.Avoid/use carefully anaesthetic drugs that
interfere with CBF autoregulation (e.g. volatile anaesthetics)
Avoid sudden increases in MAP and associated increases in ICP caused by
stress, pain, surgical stimulation and laryngeal stimulation. Provide adequate
analgesia. Ensure adequate depth of anaesthesia before intubation
Avoid hypercapnia (PaCO2 >40 mmHg) and associated increased ICP.
Use positive pressure ventilation during anaesthesia.Avoid hyperventilation
(PaCO2 <30 mmHg) except in an emergency to avoid brain herniation. Do
not decrease PaCO2 below 30 mmHg
Avoid hypoxaemia (PaO2 <80 mmHg) by providing oxygen supplementation
during induction, maintenance and recovery from anaesthesia
Select anaesthetic agents that decrease CMR (e.g. propofol).Avoid increase
in CMR by preventing or controlling seizures, maintaining normothermia and
avoiding anaesthetic agents that increase CMR (e.g. ketamine)
Avoid interference with jugular venous blood flow and associated venous
congestion and increased ICP.Avoid jugular obstruction, excessive airway
pressure during ventilation and fluid overload. Mild head elevation (15–30
degrees) will encourage venous drainage
  406 ‘Flow-by’ oxygen therapy is useful for providing
oxygen supplementation to animals that will not tolerate a
mask over their face.
Table 99 Considerations for anaesthetizing animals with intracranial diseaseManual ventilation with a close-fitting mask during
induction of anaesthesia (407) may be necessary to ensure
normocapnia until the anaesthetic depth is sufficient to
minimize reflex responses (i.e. cough, increased heart
rate and MAP) to endotracheal intubation. Once an oral
ETT has been positioned and secured in place, ventila-
tion via the tube is commenced. (Note:When ventilating
via a mask, oxygen can be forced into the stomach,
leading  to  gastric  distension.  Should  this  occur,  a
stomach tube can be passed once the animal is adequately
anaesthetized and the stomach deflated.)
To maintain adequate cardiovascular and respiratory
function  during  induction  of  anaesthesia,  the  use  of
short-acting  agents  that  can  be  carefully  titrated  to 
effect  without  excitation  is  preferred.  Drugs  that 
minimally interfere with regulation of cerebral perfusion
are also preferred. The advantages and disadvantages of
different intravenous anaesthetic agents in the neurolog-
ical patient are provided in Table  100. Propofol is the
agent the authors most frequently use in animals with
intracranial disease. The administration of ‘co-induction’
agents  with  fewer  depressant  effects  on  the  cardio-
vascular and respiratory systems can be used to reduce
the dose of the more depressant induction drugs. Co-
induction agents (see Table 101, p. 540) are administered
immediately prior to the induction agent and are usually
given intravenously. 
To  minimize  coughing  in  response  to  endotracheal
intubation, it is important to ensure that the depth of
anaesthesia  is  adequate.  The  depth  of  anaesthesia
required to prevent a response to intubation is compara-
ble to that required for major surgery. It is common prac-
tice in cats to apply topical local anaesthetic (lidocaine) to
the larynx before intubation (408). This is particularly
effective for preventing the autonomic response to intu-
bation and it is useful for canine patients as well. In
canine patients, use of co-induction agents such as lido-
caine (1–2 mg/kg) and opioids (e.g. fentanyl, 1–5 µg/kg)
intravenously can also help reduce stimulation of the
larynx during intubation. 
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  407 Ventilation via a tight-fitting mask may be
necessary during induction to ensure adequate CO2
removal and delivery of oxygen.
  408 Application of topical lidocaine to the cat’s larynx,
after an adequate depth of anaesthesia has been achieved.EMERGENCY NEUROANAESTHESIA 539
Table 100 Intravenous sedatives and induction agents for use in animals with 
central nervous system disease
AGENT CBF DIRECT  CMR ICP SEIZURE COMMENT DOSE
REGULATION CARDIOVASCULAR ACTIVITY RATE*
EFFECTS
Acepromazine
Alpha-2 
agonists
Opioids
Benzodiazepines
Lidocaine
Thiopentone
Propofol
Ketamine
CBF = cerebral blood flow; CMR = cerebral metabolic rate; ICP = intracranial pressure; NR = not reported; BP = blood pressure;
HR = heart rate; CO = cardiac putput;VD = vasodilatation;VC = vasoconstriction.
* Note:These dose rates are based on those used in normal animals and lower doses may be required in animals with CNS disease.
NR
  Flow-
metabolic
coupling
Normal
Normal
Normal
Normal
Normal
Normal
   BP
 BP then  BP
  HR 
+/–   BP
No direct
vascular effects
  BP:VD and 
  CO
  BP:VD and
 CO
  BP:VD and
 CO
  HR and BP 
NR
 
 
 
 
  
  
  
 
-
 
 
 
  
  
 
 
 
 
  
Low
dose:  
High
dose:  
 
 
 
Avoid in intracranial
disease. Useful anxiolytic
in spinal disease.
Contraindicated in hypo-
volaemic patients
Avoid in intracranial
disease. Useful in fractious
animals. Care in 
hypovolaemic patients
Reduce the required dose
of induction and
maintenance agents.
Reduce response to
intubation and surgical
stimulus
Possible sedative/
anxiolytic. Reduce
induction agent.
Potentiate respiratory
depression of other 
agents
Reduce response to
intubation and extubation.
Decrease seizures.
Analgesia (see Chapter
30)
Excitement in unsedated
animals.Accumulates with
repeated dosing
Excitement-free induction.
Suitable for maintenance
of anaesthesia in dogs
with intracranial disease
Avoid in animals with
intracranial disease.
Avoid in animals at risk of
seizures (e.g. post
myelography)
0.01–0.05
mg/kg IM
Dogs: 2–10
µg/kg IM 
Cats: 5–20
µg/kg IM
See Table 102
and
Chapter 30
Diazepam,
0.1–0.5 
mg/kg IV;
midazolam,
0.1–0.5 mg/kg
IV or IM
Co-induction:
1 mg/kg IV 
Up to 10
mg/kg IV
Induction:
up to 2–4
mg/kg IV.
Maintenance:
0.2–0.4 mg/kg/
minute
1–2 mg/kg IVSPECIFIC MANAGEMENT ISSUES 540
Table 101 Co-induction agents for use in animals with central nervous system disease
AGENT  DOSE* AND TIMING COMMENTS
Butorphanol
Fentanyl
Diazepam
or Midazolam
Lidocaine
*Lower end of dose range is recommended in critically ill animals.
0.1–0.2 mg/kg IV 1–2 minutes
prior to induction
1–5 µg/kg IV 5 minutes prior to
induction
0.1–0.2 mg/kg IV immediately
prior to induction
1–2 mg/kg IV 1–2 minutes prior to
induction
Potent antitussive. Mild analgesia only: avoid in surgical
or animals in pain.Antagonize effects of mu agonists
Bolus administration can cause significant bradycardia.
Exacerbates respiratory depression of induction agent.
Capnography and appropriate manual or mechanical
ventilation should be commenced.Also useful for
reducing the autonomic response to endotracheal
intubation
Negligible cardiovascular depression. Can cause 
disinhibition and paradoxical excitement: follow with
induction agent immediately. May exacerbate respiratory
depression of induction agent. Capnography and
appropriate manual or mechanical ventilation should be
commenced
DO NOT USE IN CATS. Can exacerbate cardiovascular
depression of other agents.Also useful for reducing the
autonomic response to endotracheal intubation
Table 102 Opioids used intraoperatively to control pain and stabilize anaesthesia
OPIOID ADVANTAGES DISADVANTAGES COMMON DOSE RATES*
Fentanyl
Alfentanil
Remifentanil
* Doses are a guide only and should be titrated on an individual patient basis.
Potent analgesia (full mu agonist).
Short acting after bolus 
administration (15–20 minutes).
Suitable for infusion 
Potent analgesia (full mu agonist).
Fast onset: 1 minute. Short duration
after bolus administration 
(5 minutes). Suitable for infusion
Potent analgesia (full mu agonist).
Very short acting (1–2 minutes).
Suitable for infusion. Duration of
action is constant regardless of
duration of infusion
Marked respiratory depression at
higher doses. Duration of action
increases with duration of infusion
Marked respiratory depression at
doses used intraoperatively.
Duration of action increases with
duration of infusion
Marked respiratory depression at
doses used intraoperatively.Very
rapid recovery: additional
analgesia required before
stopping infusion
Bolus: 1–2 µg/kg IV
q15–20 minutes.
CRI: 0.2–0.7 µg/kg/min
0.5–2 µg/kg/minute
0.2–0.7 µg/kg/minuteMaintenance of anaesthesia 
Following induction of anaesthesia it is essential to select
drugs and apply techniques that will either decrease or
minimally increase ICP. 
Total intravenous anaesthesia
Total intravenous anaesthesia (TIVA) with suitable agents
provides the best conditions for the maintenance of anaes-
thesia in the neurological patient, providing normocapnia
(P’ETCO2 30–35 mmHg [4–4.7 kPa]) and systemic BP
are maintained. TIVA can be achieved with variable rate
infusions of propofol (0.2–0.4 mg/kg/minute) or target
controlled infusion (TCI) of propofol (2.5–3.5 µg/ml of
blood) using specialized infusion equipment. Propofol is
frequently  infused  in  combination  with  short-acting
opioids (409) (see Table 102) to allow the dose of propofol
and, therefore, its associated side-effects to be reduced.
Additional  information  on  TCI  can  be  found  in  the
Further reading list for this chapter.
The  use  of  opioids  (e.g.  fentanyl  (0.2–0.7  µg/kg/
minute, remifentanil 0.2–0.7 µg/kg/minute) in combina-
tion with propofol allows the dose of propofol required
for maintenance of anaesthesia and, in turn, the cardio-
vascular side-effects, to be reduced. 
TIVA is the authors’ preferred technique for canine
neurosurgical patients and unstable patients requiring
diagnostic imaging. The TIVA protocol utilizing propo-
fol in cats is less well established and less commonly prac-
tised.  Cats  are  inefficient  metabolizers  of  propofol,
predisposing to prolonged recoveries. Their RBCs are
also more prone to the oxidative effects of the propofol
(this may cause a Heinz body anaemia). Alfaxalone may
prove to be a suitable alternative, as it has a similar phar-
macokinetic profile to that of propofol, thus making it
ideal for infusion. Infusion rates of alphaxalone currently
used clinically in healthy animals range from 0.07–0.1
mg/kg/minute. However, appropriate dose rates for use
in neurological patients have not been determined and
the quality of recoveries in these patients is not known. 
Inhalation anaesthesia
Inhalation anaesthesia can be used for short anaesthetics in
stable neurological patients. It is preferred by many anaes-
thetists for maintenance of anaesthesia in cats given the
concerns about using propofol by infusion. The character-
istics of inhalation agents are summarized in Table  103
(next page).
Sevoflurane and isoflurane have the least effect on
ICP providing the dose is minimized and the animals are
ventilated to normocapnia. As described below, infusion
of short-acting opioids is a useful technique for reducing
the required dose of inhalation agent. Despite efforts to
prevent herniation of the brain, there are still anecdotal
reports of this life-threatening complication occurring
when  these  agents  are  used  to  maintain  anaesthesia
during  intracranial  surgery  in  small  animals.  Other
volatile agents, such as halothane, desflurane and N2O,
have a marked effect on ICP and are best avoided. 
Maintain adequate ventilation and oxygenation
To maintain adequate ventilation and ensure normocap-
nia  (PaCO2 35–40  mmHg  [4.7–5.3  kPa];  P’ETCO2
30–35 mmHg [4–4.7 kPa]), the use of IPPV and meas-
urement of end tidal CO2concentration breath by breath
are essential.
To  maintain  oxygenation  during  diagnostic  proce-
dures  and  surgery  it  is  not  uncommon  to  use  high
inspired concentrations of oxygen during anaesthesia.
For long-term ventilation the FiO2 is ideally adjusted to
the minimum required to maintain PaO2 >80 mmHg
(10.7 kPa) and minimize the risk of lung damage. In
animals with concurrent pulmonary pathology, ventila-
tion strategies employing PEEP may be required to
maintain oxygenation. (For more details on IPPV and
PEEP see Chapter 2.) 
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  409 Propofol can be administered by variable rate
infusion where the rate is adjusted by the operator.Monitoring pulmonary function during anaesthesia is
essential to ensure normocapnia (PaCO2 35–40 mmHg
[4.7–5.3  kPa])  and  adequate  oxygenation  (PaO2 >80
mmHg [10.7 kPa]). For short anaesthetic procedures,
such as for diagnostic imaging or CSF sampling, capnog-
raphy and pulse oximetry are adequate for monitoring
ventilation and oxygenation. For unstable patients or
animals undergoing long procedures, such as surgery,
analysis of serial arterial blood gas samples is essential.
(For details on monitoring techniques, see Chapter 2.)
Maintain perfusion and cerebral perfusion pressure
To maintain CPP in patients with increased ICP, it is rec-
ommended that mean BPis maintained between 70 and
80 mmHg and systolic BP above 100 mmHg. For short
procedures in stable patients undergoing MRI or CT,
non-invasive BP monitoring is adequate. For unstable
patients or for monitoring during surgical procedures,
invasive, direct monitoring of arterial BP and CVP is
preferred. (For details on BP and CVP monitoring see
Chapter 2.)
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Table 103 Inhalation agents for use in animals with central nervous system disease
AGENT CBF DIRECT  CMR ICP SEIZURES COMMENT
REGULATION CARDIOVASCULAR
EFFECTS
Halothane
Isoflurane
Sevoflurane
Desflurane
Nitrous oxide
CBF = cerebral blood flow; CMR = cerebral metabolic rate; ICP = intracranial pressure;VD = vasodilation; MAP = mean arterial pressure;
IPPV = intermittent positive pressure ventilation.
Autoregulation:   
Flow-metabolism
coupling:  
Chemical regulation:
 
Autoregulation:  
Flow-metabolism
coupling:  
Chemical regulation:
normal
Autoregulation:  
Flow-metabolism
coupling:  
Chemical regulation:
normal
Autoregulation   
Flow-metabolism
coupling:  
Chemical regulation:
normal
Not reported
Cerebral VD 
   MAP
Cerebral VD
   MAP
Cerebral VD 
   MAP
Cerebral VD 
   MAP
Potent cerebral
vasodilator.
Minimal systemic
effects
 
 
 
 
No
effect
   
 
 
  
 
None
None
Reported
in humans
None
None
Avoid in neurological
patients
IPPV required. Rapid
recovery. Use balanced
anaesthesia to reduce
dose and side-effects in
neurological patients
IPPV required.Very
rapid recovery. Use
balanced anaesthesia
to reduce dose and
side-effects in neuro-
logical patients
IPPV required.
Very rapid recovery.
Use balanced
anaesthesia to reduce
dose and side-effects in
neurological patients
Avoid in patients with
increased ICPReduce cardiovascular depression associated with
maintenance agents 
As  most  anaesthetic  agents  cause  dose-dependent
decreases in BP, it is preferable to combine short-acting
anaesthetic agents that can be titrated to effect with
short-acting opioids that cause minimal cardiovascular
depression. This will reduce the required dose of the
selected maintenance agent in a dose-dependent fashion.
The doses of opioids commonly used for maintenance of
anaesthesia  are  provided  in  Table  102.  Animals  with
severe neurological impairment may require lower doses.  
An expected side-effect of administration of these
potent opioids is respiratory depression. Even at low
doses, significant hypoventilation may occur and IPPV
may be required to maintain normocapnia. Both alfen-
tanil and fentanyl will accumulate after a period of infu-
sion, so it may be prudent to terminate or reduce the
infusion rate prior to the end of anaesthesia to ensure
adequate  ventilation  on  recovery.  Remifentanil  does
not accumulate and has a duration of action of approxi-
mately 3minutes regardless of the duration of infusion.
Maintenance of normal fluid balance 
Providing  animals  have  normal  fluid  and  electrolyte
balance prior to anaesthesia, fluid therapy during anaes-
thesia initially consists of isotonic, polyionic crystalloids
administered  at  10  ml/kg/hour.  Subsequent  infusion
rates and types of fluid will depend on losses and cardio-
vascular performance during anaesthesia. Measurement
of CVP,  arterial BP and urine output (UOP) is the best
way to assess the response to fluid therapy. (For details on
selection of fluids and rates for varying conditions see
Chapter 31; for details of techniques for monitoring of
BP, CVP and UOP see Chapter 2.)
Avoid sudden/marked increases in blood pressure
Various stimuli during anaesthesia, including nocicep-
tion from surgical stimulation, can cause increases in BP,
which in a diseased brain may result in an increase in
CBF and ICP. To minimize sudden or marked increases
in BP during anaesthesia, the continuous infusion of an
opioid (as described above) can help minimize this sym-
pathetic stimulation and the haemodynamic responses to
surgery. This in turn will contribute to the maintenance
of stable BP and CBF.
Maintain venous drainage from the head
Diagnostic  imaging  procedures  and  craniectomy  are
invariably  performed  with  the  patient  positioned  in
sternal recumbency with the head level with the spine
(410). This position is excellent for ensuring adequate
lung expansion and also encourages venous drainage
from the head. However, it is important to ensure that
the jugular veins are not occluded when the animal is
placed in this position, as this will lead to venous conges-
tion within the brain and marked increase in ICP. For
animals  in  lateral  recumbency,  mild  head  elevation
(15–30 degrees) is also recommended to encourage cere-
bral venous drainage. 
Measurement of CVP is generally performed via a
catheter inserted into the jugular vein. This may increase
the risk of disturbance to venous return and increased
ICP.  Methods  for  reducing  the  interference  with
venousreturn are described in Chapter 2. 
The use of IPPV may also impede venous return
fromthe head during the inspiratory phase of ventilation.
To minimize this adverse effect, the inflation pressures
required to maintain normocapnia can be reduced by
administration of NM blockade using drugs such as
atracurium.  Atracurium  is  initially  administered  at
0.2–0.5 mg/kg IV. This is followed by increments of
0.1mg/kg, which is administered according to NM activ-
ity assessed using a nerve stimulator. 
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  410 In animals with intracranial disease, venous
drainage from the head is maintained by positioning in
sternal recumbency with the head at the same level as 
the spine.Maintain body temperature 
Body  temperature  should  be  maintained  as  close  to
normal as possible. Hypothermia has numerous adverse
effects on the patient including: 
•C a r d i o v a s c u l a r   s y s t e m   d e p r e s s i o n   w i t h   b r a d y c a r d i a
and hypotension.
•S u p p r e s s i o n   o f   t h e   i m m u n e   s y s t e m   a n d   a n   i n c r e a s e d
risk of infection.
•D e l a y e d   h e a l i n g .
•I n t r a -   a n d   p o s t o p e r a t i v e   c o a g u l o p a t h y   a n d
increased blood loss.
•S l o w   r e c o v e r y .
•S h i v e r i n g   o n   r e c o v e r y ,   w h i c h   i n c r e a s e s   o x y g e n
demand when oxygen delivery may be
compromised.
•P r o l o n g e d   h o s p i t a l   s t a y s .
Hyperthermia,  on  the  other  hand,  increases  CMR,
which increases CBF and can lead to increases in ICP and
further reductions in CPP. 
It is important to remember that head trauma (espe-
cially  if  it  involves  the  hypothalamus)  can  result  in
impaired thermoregulation. Close monitoring of the
temperature in these animals is imperative and appropri-
ate therapy should be initiated when abnormalities arise.
Methods for maintaining normal body temperature in
animals with neurological disease will be discussed in
more detail in the NM disease section below.
Recovery from anaesthesia
The aims during the recovery period are to achieve a
smooth  emergence  from  anaesthesia  with  minimal
excitement, coughing or straining, and adequate ventila-
tion (411). The timing of extubation is a compromise
between ensuring the animal can protect its own airway,
breathe spontaneously and maintain normocapnia, while
avoiding stimulation that can lead to increases in arterial
BP and coughing.
Ensure adequate ventilation
Reduce rates of opioid infusions
If high infusion rates of opioids have been used during
surgery, it is important that the infusion rate is reduced in
preparation for recovery. Once the patient is extubated
and IPPV can no longer be delivered, it is imperative that
the  patient  can  breathe  spontaneously.  Extubation
should therefore only be performed when the patient can
spontaneously ventilate adequately (check the capno-
graph or blood gases). 
When using either an alfentanil or fentanyl infusion,
the rate should be reduced approximately 30 minutes
prior to extubation. This will depend to some extent on
the duration of infusion and the total amount of drug that
has been delivered (the higher the dose and the longer
the infusion, the more time required to reduce serum
concentrations).
Remifentanil does not accumulate and activity rapidly
disappears after infusion is stopped, allowing prompt
return to spontaneous ventilation. The disadvantage is
that the analgesic activity is also rapidly terminated. If
continued analgesia is required, another opioid must be
administered prior to turning off the remifentanil infu-
sion. This may be in the form of a long-acting opioid
such  as  methadone.  Alternatively,  infusion  of  short-
acting opioids at a lower dose (see Chapter 30) can be
used to provide postoperative analgesia so long as the
patient can breathe spontaneously. 
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  411 Following brain surgery, animals should be
recovered in a controlled, quiet manner. Extubation is a
balance between ensuring normal ventilation and
preventing coughing when the endotracheal tube is
removed.Assess adequacy of spontaneous ventilation
periodically
When preparing to extubate, the ETT tie is undone and
the cuff left inflated. As the depth of anaesthesia decreas-
es, trial periods of apnoea are performed. If spontaneous
ventilation and maintenance of normocapnia occur, then
the animal can be extubated; otherwise IPPV is reintro-
duced before P’ETCO2 exceeds 45 mmHg. Once extu-
bated, the patency of the airway needs to be assessed,
particularly in animals with brachycephalic airway syn-
drome. It is important to have ready access to an induc-
tion agent in case immediate reintubation is required. 
Minimizing coughing and hypertension on recovery
To minimize laryngeal stimulation, the administration of
agents  such  as  fentanyl  or  lidocaine  can  be  used  as
described for intubation. At the end of anaesthesia, the
drugs are given just prior to expected extubation. Alter-
natively, in animals requiring ongoing analgesia, a con-
tinuous infusion of fentanyl (2–5 µg/kg/minute) can also
help reduce coughing on extubation. 
Hypertension in the recovery period despite ade-
quate analgesia can be treated by administration of  
receptor antagonists or blockers (e.g. esmolol, 50–200
µg/kg/minute CRI). More details on hypertension in
neurological patients can be found in Chapter 2.
Minimizing agitation in the perianaesthetic period
Agitation is not uncommon in animals with intracranial
disease. Administration of opioid analgesics will ensure
the agitation is not caused by pain. If it persists, then
sedative agents such as acepromazine or dexmedetomi-
dine will be required, but as these agents have adverse
effects on the CNS and the cardiovascular system, their
benefits for controlling agitation and calming the patient
need to be weighed against the adverse effects that may
occur. If administration of these agents is deemed neces-
sary, low doses should be used and blood volume and BP
should  be  normalized  before  administration.  For
example,  the  authors  have  used  acepromazine  (5–10
µg/kg IM) to control agitation in dogs post craniectomy
when other methods of controlling the agitation have
failed and the animal is considered at risk of injury from
the agitation. Trazodone hydrochloride, a triazolopyri-
dine derivate and member of the phenylpiperazine class
of drugs, can also be considered as an anxiolytic in these
situations (see Further reading).
SPINAL DISEASE
Considerations 
Anaesthesia in animals with spinal disease should be
designed  to  maintain  spinal  perfusion  and  minimize
further neurological injury. As a result, many of the prin-
ciples of anaesthesia for patients with intracranial disease
are relevant to patients with spinal disease. Considera-
tions for anaesthetizing animals with spinal disease are
outlined in Table 104 (next page).
Stabilization 
Animals  with  spinal  trauma  frequently  have  other
injuries.  Patients  with  spinal  disease  may  have  had
reduced access to water due to reduced mobility (412).
Stabilization of pulmonary and cardiovascular functions
and correction of fluid and electrolyte deficits should be
performed prior to anaesthesia. A full clinical examina-
tion should be performed with particular attention paid
to the function of the cardiovascular and respiratory
systems. 
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  412 Spinal patients may have reduced access to water
due to immobility. This may predispose to dehydration if
supplemental fluid is not provided. Dogs, such as the one
in this photograph, will need to be administered fluids
intravenously or frequently ‘by hand’.Guidelines for sedating and anaesthetizing
animals with spinal disease
Premedication
Premedication is important not only to provide analgesia
and minimize the dose of induction agent required, but
also to increase the ease of handling without the need for
excessive physical restraint, which may be dangerous for
these patients.
Choosing drugs and drug combinations
Opioids form the basis for premedication of animals with
spinal disease and are generally administered on their
own  to  patients  with  other  systemic  abnormalities.
Avariety  of  other  agents  can  be  used  in  conjunction  with
opioids to provide additional sedation if required. The
doses and advantages and disadvantages of these agents
are outlined in Table  101. Acepromazine is useful in
anxious but otherwise stable animals. Medetomidine can
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Table 104 Considerations for anaesthetizing animals with spinal disease
CONSIDERATION MANAGEMENT
Maintain perfusion
Pain
Anxiety
Mechanical instability
Respiratory insufficiency
Maintain airway
Blood loss
Correct deficits in circulating blood volume and body water. Use agents/techniques that
minimally depress cardiovascular function
Most spinal diseases are painful and effective analgesia (e.g. full mu agonists) is necessary
Anxiety is common in paralysed animals and decreases the pain threshold.Administering
anxiolytics is an important part of pain management in spinal patients
Animals need to be moved carefully to minimize further trauma to the spinal cord,
particularly when a fracture or luxation is suspected. Intubation of animals with suspected
instability of the cervical spine should also be performed carefully. Flexion and extension of
the head should be avoided
Cervical spinal lesions can interfere with innervation of the diaphragm and intercostal
muscles, leading to inadequate ventilation and respiratory arrest. Sternal recumbency
during surgery restricts movement of the diaphragm and thus mechanical ventilation is
recommended during surgery to ensure adequate ventilation
Ventral approaches to the cervical spine require retraction of the trachea and may partially
or completely obstruct the endotracheal tube
Blood loss during surgery can be significant and needs to be monitored closely by weighing
swabs and measuring fluid in suction bottles.Transfusion is indicated if >20% of
circulating blood volume is lost or if signs of hypovolaemia (increased heart rate without
increased MAP, pale mucous membranes) are observed
be used in extremely anxious or fractious animals that are
normally hydrated and cardiovascularly stable. Benzodi-
azepines are unpredictable and unreliable sedatives in
healthy dogs and cats, but may provide useful sedation in
critically ill animals. Medetomidine and benzodiazepines
both  cause  skeletal  muscle  relaxation  and  should  be
avoided in animals with unstable spinal fractures (413).
Ketamine is another option in normovolaemic cats with
normal renal function in combination with opioids, ace-
promazine or benzodiazepines. However, ketamine is
extremely painful when injected intramuscularly. This
may cause additional discomfort to animals already in
pain. In addition, sudden uncontrolled movement in
response to the injection may be detrimental in animals
with an unstable spinal fracture. Induction
Minimize further damage to spinal cord 
A rapid and controlled induction of anaesthesia with
minimal struggling is best achieved with intravenous
agents. Endotracheal intubation should be performed
carefully with adequate support of the head and neck,
particularly in animals with cervical spinal cord injury
(414). Intubation is facilitated by the use of a laryngo-
scope (415). Excessive extension of the neck should be
avoided in dogs with caudal cervical lesions, while exces-
sive flexion should be avoided in animals with AA sublux-
ation or other cervical fractures. 
Select induction agents that minimally interfere with
spinal perfusion
Selection of an appropriate induction agent is based on
the same basic principles as those described for animals
with intracranial disease. The characteristics of the intra-
venous  agents  and  suggested  doses  are  described  in
Table 100. To decrease the required dose of intravenous
induction agent and to minimize cardiovascular depres-
sion, concurrent administration of a potent opioid, such
as fentanyl or a benzodiazepine, can be used during
induction (Tables 101 and 102).
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  413 Handling and choice of premedication should be
performed carefully in animals with unstable spinal
fractures, such as that noted on this lateral thoracolumbar
radiograph (arrow).
  414 For animals with cranial spinal lesions, such as the
C2/C3 disc extrusion seen on this sagittal MR image
(arrow), intubation should be performed with support of
the head and neck.
  415 Intubation is best performed with the animal in
lateral recumbency. Use of a laryngoscope will aid visuali-
zation of larynx. Maintenance of anaesthesia
Select agents that maintain spinal perfusion
Maintenance of anaesthesia is usually performed with
inhalation agents. As autoregulation of perfusion to the
spinal  cord  and  chemoreceptor  response  to  carbon
dioxide are better maintained with isoflurane and sevo-
flurane than halothane, these are the preferred inhalation
agents. Nitrous oxide is reported to increase ICP as a
result  of  cerebral  vasodilation,  so  is  best  avoided  in
patients with intracranial disease. Whether the same pre-
cautions are warranted in animals with spinal cord injury
and compression is not known. 
Infusion of short-acting opioids can also be used 
in  conjunction  with  inhalation  agents.  These  agents
provide analgesia, which is essential in most animals with
spinal disease, and will help reduce the dose and thus the
amount  of  cardiovascular  depression  observed  with
inhalation agents. Details of the use of these opioids are
described in the section on intracranial disease. 
Maintenance of anaesthesia can also be performed
with  a  TIVA  technique  as  described  for  intracranial
disease. TIVA is especially useful for dogs requiring
surgery of the cranial cervical spinal cord where manipu-
lation of the cervical spinal cord and/or brainstem may
occur (e.g. repair of AA instability). 
Maintain adequate ventilation 
IPPV  is  recommended  during  anaesthesia  in  spinal
patients  for  several  reasons.  Firstly,  the  detrimental
effects  of  inhalation  agents  on  spinal  blood  flow 
regulation can be minimized by maintaining normo-
capnia. Secondly, surgical access frequently requires that
the animal is positioned in sternal recumbency, which
can interfere with diaphragmatic excursions and impair
ventilation. Finally, the dose rates of the opioid agonists
recommended for intraoperative use produce marked
respiratory depression and therefore necessitate IPPV. 
Maintain adequate perfusion
Intravenous fluid therapy is essential during anaesthesia
in all spinal cases to maintain fluid balance, adequate BP
and  perfusion  of  the  spinal  cord.  In  hypovolaemic
animals, the volume deficit should be replaced before
anaesthesia.  Intraoperative  blood  loss  can  be  unpre-
dictable  and  surprisingly  high  during  spinal  surgery.
Blood loss should be estimated regularly by counting
blood-soaked swabs, weighing swabs (1 ml of blood
weighs approximately 1.03 g) or measuring the volume of
fluid in suction bottles (taking into account dilution from
irrigation fluids). 
Blood loss can also be estimated from the PCV of
fluid in the suction bottle. This technique requires an
accurate measurement of the patient’s PCV at the time
of blood loss. The PCV prior to anaesthesia may not be
representative of the PCV during anaesthesia. The PCV
may decrease due to splenic sequestration of RBCs in
response to anaesthetic agents (propofol, barbiturates)
and dilution by intravenous fluid therapy. If an accurate
estimate of the PCV of the patient prior to haemorrhage
is known, the amount of blood in the bottle can be
estimated using the following:
Amount of blood lost (ml)
=PCV of flush in bottle  total volume of fluid in bottle 
PCV of patient at time of haemorrhage 
A blood transfusion is indicated when blood loss exceeds
20% of the circulating blood volume or haemoglobin
concentration is <80 g/l (<8 g/dl). Blood loss of less than
20%  can  be  managed  by  administrating  crystalloids 
+/–  colloids  such  as  hetastarch  (maximum  dose
20 ml/kg/day). (For more details on fluid therapy see
Chapter 31.)
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  416 Heat and moisture exchange devices can be placed
between the endotracheal tube and the breathing circuit
to help reduce heat and moisture loss from animal.Maintain body temperature
Heat loss can be a problem, particularly when spinal cord
injury causes sympathetic nervous system imbalance and
peripheral vasodilation. Monitoring core body tempera-
ture should be performed during anaesthesia. Heat loss
can be prevented during anaesthesia by heat pads, warm
water beds or warm air blowers and ‘blankets’. Heat and
moisture exchange devices (416) can be placed between
the  endotracheal  tube  and  the  breathing  system  to
promote warmth and humidification of inspired gases.
Monitoring
During diagnostic imaging and surgery in animals with
spinal disease, non-invasive monitoring of cardiopul-
monary function with electrocardiography, non-invasive
BP measurement, capnography and pulse oximetry is
generally adequate. In animals where cardiopulmonary
dysfunction  (e.g.  cranial  cervical  surgery,  trauma
involving multiple organ systems) or excessive blood loss
is expected, invasive BP measurement is recommended.
Monitoring techniques have been discussed in detail in
Chapter 2. 
Recovery 
It is essential that the provision of analgesia is continued
into the postoperative period to ensure a calm and com-
fortable recovery. In some cases the use of low-dose seda-
tives, such as acepromazine (0.01–0.02 mg/kg IM or IV)
or dexmedetomidine (0.5–1.0 µg/kg IV bolus or infusion
of 0.5–1.0 µg/kg/hour), may be required in extremely
stressed or agitated animals exhibiting signs of subopti-
mal emergence. However, these drugs should only be
used in animals with normal cardiovascular function.
Trazodone (see p. 545) can also be used to treat postoper-
ative anxiety. (For details on possible postoperative anal-
gesia see Chapter 30.)
NEUROMUSCULAR DISEASE 
Considerations
Considerations  for  anaesthetizing  animals  with  NM
disease are outlined in Table 105. The general principles
for anaesthetizing these patients are similar, with some
differences  depending  on  the  type  of  NM  disease
present. These principles are described in more detail in
regard to premedication, induction, maintenance and
recovery of anaesthesia. 
Stabilization 
Fluid and electrolyte abnormalities are common in these
patients due to immobility and an inability to eat and
drink.  These  deficits  need  to  be  corrected  prior  to
anaesthesia when possible. Fluid and acid–base abnor-
malities associated with toxicities, such as metaldehyde,
will also need to be corrected prior to anaesthesia (see
Chapter28). 
Animals with aspiration pneumonia should be stabi-
lized as much as possible prior to anaesthesia. Antibiotic
and oxygen therapy forms the basis of symptomatic treat-
ment in these animals. 
Premedication 
The use of premedication in animals with peripheral
NM disease will depend on the type of disease that is
present, how painful that disease is and how urgent the
need  for  anaesthesia  is  (e.g.  an  animal  with  airway
obstruction requires immediate anaesthesia). In anxious
animals, the judicious use of sedatives may be needed to
facilitate a smooth, stress-free induction. (Note:Sedation
can interfere with the maintenance of a patent airway and
increase the risk of upper respiratory tract obstruction
and aspiration. If used, low doses are recommended and
animals should be constantly monitored for any adverse
effects.) 
In animals with painful NM disease (which is uncom-
mon), premedication should include an opioid, either
alone or in combination with other agents. Opioid pre-
medicants should also be given to animals requiring
muscle  and  nerve  biopsies  and  animals  undergoing
painful diagnostics such as electromyography. 
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Maintain oxygenation 
The patient should be pre-oxygenated for 5–10 minutes
prior to induction when possible. If an animal objects to
the placement of a face mask, the use of flow-by oxygen is
recommended. Flow-by oxygen is preferred in animals
predisposed to hyperthermia, because masks encourage
re-breathing of warm expired gases. Pre-oxygenation
increases  the  concentration  of  oxygen  in  the  func-
tionalresidual capacity of the lung and delays the onset of
hypoxaemia in the event of a difficult intubation or in
patients with cardiovascular or respiratory compromise.
Prevent regurgitation and aspiration
Induction of anaesthesia should be performed with the
patient  in  sternal  recumbency  (417).  If  there  is  an
increased risk of regurgitation (e.g. megaoesophagus),
cricoid pressure should be applied. Cricoid pressure is
maintained until the ETT is placed and secured in the
airway with the cuff inflated. Suctioning of the pharynx,
oesophagus and stomach should be performed as soon as
the airway is secure to minimize the risk of aspiration
during anaesthesia (if the cuff becomes deflated). If vom-
iting  or  regurgitation  occurs  during  induction  of
anaesthesia and before the airway is protected by the
presence of an ETT, the animal should immediately be
positioned with its head over the edge of the table to
allow  gravity-assisted  drainage  of  the  pharynx.  The
pharynx and oesophagus should be suctioned before
intubation is performed. 
Induction of anaesthesia should be performed with
short-acting  intravenous  agents  that  facilitate  rapid
control of the airway. Furthermore, a prompt recovery
from anaesthesia is important in order for the patient to
regain control of its airway as soon as possible. Agents
such as propofol and alfaxolone allow rapid recovery;
however, in animals at risk of obstruction, titration of
these agents to effect can delay intubation. Furthermore,
bolus  administration  can  lead  to  marked  decreases 
in BP. To reduce the dose and thus the side-effects, 
co-induction  agents  (fentanyl  +  short-acting  benzo-
diazepines) can be administered immediately prior to an
intravenous induction agent. This combination of agents
will invariably cause apnoea and therefore animals should
be  ventilated  as  soon  as  intubation  is  performed.
Ketamine should be avoided in animals with tetanus and
increased  muscle  activity.  Thiopentone  allows  rapid
control of the airway, but the recovery period is likely to
be prolonged.
Maintenance of anaesthesia
Selection of agent
Agents with a short duration of action, thus allowing
rapid recovery, are preferred. Inhalation agents, such as
isoflurane, sevoflurane and desflurane, all have physico-
chemical properties that ensure a rapid clinical response
to changes in vapourizer settings. In addition, recovery
from anaesthesia is relatively rapid, with prompt return
of airway reflexes. 
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  417 Animals that are at risk of regurgitation during
induction should be maintained in sternal recumbency
with cricoid pressure applied until the endotracheal tube
is placed and cuff inflated.Ensure adequate ventilation 
Mechanical ventilation is recommended in all animals
with peripheral NM disease as there is likely to be a com-
ponent of respiratory muscle involvement. IPPV should
be delivered with close monitoring of CO2concentration
in the expired gas with a capnograph or serial arterial
blood gas analyses. Monitoring of the haemodynamic
consequences of ventilation is also prudent. 
Maintain normal body temperature
Animals with NM disease may have difficulty maintain-
ing normal body temperature (see Table 105). It is there-
fore  essential  to  monitor  core  body  temperature
perioperatively in these animals. Mild decreases in body
temperature  can  be  managed  with  passive  warming
(e.g.warm air blankets or warm water beds). It is easier to
prevent hypothermia than to treat it, so all efforts to pre-
serve body temperature should be made. Although it is
unusual  for  animals  to  develop  hyperthermia  under
anaesthesia, increases in body temperature should be
managed by passive cooling.
Neuromuscular relaxation
In animals with peripheral NM disease requiring surgery
for  other  reasons  (e.g.  thoracotomy  for  thymoma
removal in animals with MG), NM relaxation may be
required to improve surgical access. Non-depolarizing
muscle relaxants can be used, but extreme care is required
as prolonged duration of skeletal muscle weakness can
occur. Depolarizing muscle relaxants such as suxametho-
nium should be avoided. 
Non-depolarizing NM blocking agents should be
administered in incremental doses with careful monitor-
ing of peripheral nerve blockade with a nerve stimulator.
There must also be facilities to provide either mechanical
or manual IPPV and assessment of adequacy of ventila-
tion (capnography or blood gas analysis). Shorter-acting
NM blocking agents, such as atracurium or vecuronium,
administered at one tenth of the usual dose, are the pre-
ferred agents. Infusions allow more precise control of the
degree of NM blockade than boluses, which create peaks
and troughs in plasma concentration and thus cause 
relative overdose and relative underdose, respectively. 
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Table 105 Considerations for anaesthetizing animals with neuromuscular disease
CONCERN CONSIDERATIONS
Pain
Dysphagia
Airway obstruction
Impaired ventilation
Impaired oxygenation
Impaired thermoregulation
Dehydration and electrolyte 
abnormalities
Presence and severity of pain will vary with the disease. Painful conditions include
polyradiculoneuritis, some myopathies and muscle and nerve biopsy patients
Weakness of pharyngeal muscles results in difficulty swallowing and predisposes 
to aspiration
Laryngeal paresis or paralysis. Laryngeal spasm (e.g. tetanus)
Mechanical ventilation frequently required due to:
•W e a k n e s s   o f   r e s p i r a t o r y   m u s c l e s   ( e . g . s n a k e   e n v e n o m a t i o n , m y a s t h e n i a   g r a v i s ,
polyradiculoneuritis, tetrodotoxin, botulism).
•S p a s m   o f   d i a p h r a g m   a n d   i n t e r c o s t a l s   ( e . g . t e t a n u s )
Dysphagia, megaoesophagus and inability to protect the airway predisposes to aspiration.
Recumbency predisposes to atelectasis. Supplemental oxygen recommended in peri-
operative period
Laryngeal dysfunction and impaired ventilation reduce ability to pant and predispose to
hyperthermia during exposure to warm environments. Muscle fasciculations and tetany
increase metabolic rate and predispose to hyperthermia. Generalized weakness prevents
shivering and predisposes to hypothermia during exposure to cold environments
Recumbent animals may have restricted access to water. Dysphagia impedes ability to eat
and drink. Regurgitation associated with megaoesophagus increases loss of water and
bicarbonate (from saliva)Recovery
Maintain adequate oxygenation and ventilation
As the animal recovers from anaesthesia, it is essential to
monitor end-tidal CO2 to ensure spontaneous ventila-
tion  is  sufficient  to  maintain  normocapnia.  These
animals will invariably have some degree of pulmonary
pathology due to aspiration or atelectasis, so oxygenation
should be monitored throughout recovery and supple-
mental oxygen provided until the animal can maintain
SpO2 >95%  when  breathing  room  air.  Initially,  this
can be  performed  via  the  ETT;  however,  following
extubation, oxygen can be provided by mask, oxygen
cage or nasal catheters. Where oxygenation is expected
to be poor for prolonged periods (e.g. animals with pneu-
monia or animals expected to be recumbent following
anaesthesia), nasal catheters should be placed before the
end of anaesthesia to provide a smooth stress-free transi-
tion from oxygenation via the ETT to the nasophar-
yngeal  catheters.  (Note: Animals  that  develop  upper
respiratory tract obstruction [e.g. laryngeal paralysis or
laryngeal spasm] following extubation may require a tra-
cheostomy to maintain adequate oxygenation and venti-
lation [see below].)
Prevent aspiration
Suctioning of the oesophagus and pharynx should be
performed prior to recovery in order to minimize the risk
of regurgitation at extubation. The animal is best posi-
tioned in sternal recumbency with the head elevated to
maximize chest excursions and respiratory function. In
addition, elevation of the head will help prevent passive
regurgitation. Should vomiting or regurgitation occur
during recovery, the animal’s head must be positioned
over the edge of the table to allow fluid or stomach con-
tents to flow out of the mouth. If the animal is still suffi-
ciently anaesthetized, the pharynx and mouth can be
cleared by suctioning and swabbing. To prevent oeso-
phagitis associated with regurgitation of gastric contents,
the oesophagus should ideally be carefully lavaged until
the fluid retrieved is clear. It is essential that the ETT is
secured in place with adequate cuff inflation when lavage
is performed. 
Maintain a patent airway
Animals with neuromuscular weakness or 
post-gastric lavage
In these animals extubation is delayed for as long as pos-
sible to ensure upper and lower respiratory muscle func-
tion is adequate. Recovery should be performed in a
quiet, dimly lit environment to minimize stimulation on
recovery. The cuff of the ETT=endotracheal tube is left
inflated until the animal is ready to be extubated. Ade-
quate analgesia must always be provided in animals with
painful diseases to optimize conditions for a smooth
emergence  from  anaesthesia.  Low-dose  infusions  of
short-acting opioids can also help reduce stimulation
from the ETT and help maintain a patent airway for
longer. 
Animals with tetanus
Although tetanus does not cause NM pathology, it is
associated  with  severe  muscle  spasms.  Extubation  in
patients with tetanus can stimulate laryngospasm. The
safest approach is to recover these animals with a tra-
cheostomy in place. If a tracheostomy is not performed,
laryngospasm can be minimized by extubating early, as
long as the patient is ventilating spontaneously. Topical
lidocaine applied to the larynx may also help. In any
case, it is essential to be prepared to perform an emer-
gency tracheostomy should laryngospam occur and if 
reintubation is too difficult. Preparing the site before-
hand is recommended to save time should a tracheo-
stomy  be  required.  The  ability  to  provide  oxygen
supplementation via an intratracheal needle or catheter
should also be available in case upper respiratory tract
obstruction occurs (see Chapter 2). (Note: This method
of providing oxygen is only suitable for short periods, as
there is no concurrent ventilation, and overinflation of
the lungs can occur because there is no outflow for the
insufflated oxygen.)
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INTUBATION AND MECHANICAL VENTILATION 
The choice of agent used to maintain anaesthesia in
animals requiring ventilation will depend on the indi-
cations for ventilation, the expected duration of ventila-
tion and whether the animal has an oral ETT or a
tracheostomy. Ventilation techniques are discussed in
Chapter  2.  Examples  of  agents  that  can  be  used  to
provide sedation or anaesthesia for ventilation are listed
in Table 106.
Dose rates
Maintenance of anaesthesia has ‘lighter’ requirements
than does surgical anaesthesia, and in some cases sedation
only may be needed. In animals intubated via tracheo-
stomy, the depth of sedation/anaesthesia will be even
lower, as the stimulus associated with oral intubation is
absent. Animals that are weak, paralysed or suffering
from  CNS  depression  will  also  require  much  lower 
doses than those with normal CNS activity. Therefore,
short-acting agents that can be titrated to achieve the
required level of sedation or anaesthesia in each individ-
ual are preferred. 
Additional considerations for paralysed animals 
The use of sedation or anaesthesia for ventilating para-
lysed  animals  warrants  special  mention.  Sedation  or
anaesthesia is not required to tolerate the presence of an
ETT; however, as they recover from paralysis, sedation
or anaesthesia will be required to maintain intubation.
The reason for this is the differential recovery of differ-
ent  skeletal  muscles  from  paralysis,  allowing  these
animals to move before being able adequately to ventilate
or protect their own airway. As a result, these animals can
start to struggle. Furthermore, it must be remembered
that even when a patient is fully paralysed they are con-
scious and responsive to their environment, therefore
some sedation and/or analgesia is required to minimize
stress and discomfort.
Nursing and airway management of the chronically
ventilated patient are covered in Chapter 2. 
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Table 106 Possible agents for sedating or anaesthetizing animals during long-term ventilation
DRUG DOSE  COMMENTS
Inhalation agents:
isoflurane/sevoflurane
Propofol
Midazolam
Fentanyl
1 minimum alveolar concentra-
tion equivalent or less
0.05–0.4 mg/kg/minute
0.05–0.2 mg/kg/hour (do not
dilute drug with Hartmann’s)
0.2–0.7 µg/kg/minute
Not recommended for long-term ventilation in animals
with intracranial disease. Isoflurane can be irritant to
airway and therefore is best avoided. May have adverse
effects in airway disease or prolonged anaesthesia
Ideal for animals with intracranial disease. Can be used
for any animal requiring sedation or anaesthesia for
ventilation
Can be used in animals with intracranial disease that
require sedation for intubation. Dysphoria observed
with prolonged infusion may cause stressful recoveries.
Use cautiously in animals with neuro-
muscular weakness
Can be used alone in paralysed animals or in
conjunction with other agents to provide
analgesia/sedationSPECIFIC CONSIDERATIONS FOR 
DIAGNOSTIC PROCEDURES 
Myelography
Myelography is associated with a risk of seizures on
recovery from anaesthesia and a variety of cardiopul-
monary abnormalities that can occur during anaesthesia,
particularly during/after contrast injection (418). 
Seizure activity
Seizure activity is a recognized adverse effect of injection
of contrast agents into the subarachnoid space. The risk
of seizures is influenced by several factors including the
volume and rate of contrast injection, the site of injec-
tion, the size of the animal, duration of anaesthesia after
injection and the position of the animal during injection.
Seizures are more commonly observed after CMC myel-
ography compared with lumbar myelography. Animals
weighing >20 kg are also observed to have a higher inci-
dence of seizures, possibly due to the relatively higher
volume of contrast injected. 
To reduce the risk of seizures, the dose rate should be
calculated from surface area rather than body weight, the
speed of injection should be slow and the head should
be elevated as soon as injection is complete to promote
the flow of contrast away from the head. The use of a
tilting table allows head elevation while keeping the
animal’s spine straight and supported.
Pharmacological  agents  that  decrease  the  seizure
threshold should be avoided. Acepromazine, ketamine
and medetomidine have been previously reported to
decrease the seizure threshold, and most of the literature
recommends that these agents are not used in animals
undergoing  myelography.  However,  the  association
between use of acepromazine and seizure activity has
become increasingly unclear and its effect may depend
on the cause of the seizure activity. The authors recom-
mend that its use be avoided whenever possible and if
required for sedation/anxiolysis, it is used carefully and at
low doses.
Seizures have been reported to occur up to 6 hours
after  contrast  injection,  so  these  animals  should  be
closely monitored during this time. If seizures occur,
administration of diazepam (0.2–1.0 mg/kg IV) is recom-
mended as the first-line treatment. 
Cardiopulmonary disturbance
Cardiopulmonary  side-effects  during  or  immediately
after the injection of contrast have been observed and
include apnoea, tachypnoea, bradycardia, tachycardia,
arrhythmias, hypotension and hypertension. Many of
these effects are associated with the discomfort or pain of
injection and can be minimized by slowing the injection
rate  and  ensuring  an  adequate  depth  of  anaesthesia
during injection. Transient increases in ICP may also be
responsible, particularly with cisternal contrast injec-
tions. Careful monitoring of cardiopulmonary function
is necessary during myelography to detect any problems
early and treat accordingly.
Magnetic resonance imaging
The main considerations for anaesthetizing patients with
intracranial and spinal disease for MRI are described in
the relevant sections earlier in this chapter. In addition,
there are several important considerations unique to
anaesthetizing a patient within a magnetic field.
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  418 Myelography is frequently performed to diagnose
intervertebral disc disease (as seen here). Performance of a
myelogram requires special considerations for anaesthesia.
(Photo courtesy Victoria Johnson)Equipment hazards
Ferromagnetic objects can become dangerous projectiles
and may result in injury and/or death to the patient or
personnel within the scanning room. It is essential that
these objects remain outside the 5 gauss line. Anaesthet-
ic machines are required to be as close to the patient as
possible to minimize the length of the breathing system
and should be composed of non-ferromagnetic materi-
als. If this is not possible, a non-rebreathing anaesthetic
circuit (e.g. Bain) can be used, as the length of the inspi-
ratory and expiratory tubes (which are coaxial) may be
effectively infinite. Non-ferromagnetic objects within a
magnetic field (e.g. ECG leads) have the potential to
induce electric currents, leading to heating and burns.
The risk of burns can be minimized by insulating the
wires, separating the wires from the skin by padding,
avoiding large loops of wire that allow the induction of
currents  and  applying  sensors  as  far  away  from  the
imaged area as possible.
Monitoring 
Monitoring of the anaesthetized patient during MRI has
inherent limitations. Equipment used for monitoring
must be MRI safe and ideally MRI compatible. Equip-
ment that is MRI safe has been demonstrated to present
no additional risk to the patient. Equipment that is MRI
compatible has been demonstrated to be both MRI safe
and to not reduce significantly the diagnostic quality of
the imaging procedure nor have its operation affected by
the scanning procedure. MRI compatible equipment is
currently  available  that  allows  distant  monitoring  of
animals during MRI. Where cost is limited, some moni-
toring equipment, such as capnography, oesophageal
stethosope and oscillometric methods of non-invasive
BP measurement, can be used if the electrical compo-
nents are outside the 5 gauss line. 
Cerebrospinal fluid collection
The collection of CSF may be performed by CMC or
lumbar puncture. CMC puncture requires flexion of the
neck, which can cause inadvertent kinking of the ETT
and respiratory obstruction. In addition, flexion of the
neck can obstruct jugular veins, impair venous drainage
and contribute to increased ICP. IPPV is essential during
CMC  puncture  to  ensure  adequate  ventilation  and
normocapnia. 
ETTs reinforced with coiled wire resist kinking and
can be used to prevent airway obstruction when the neck
is flexed for collection of CSF. As these tubes contain
metal, they are not suitable for use in animals undergoing
concurrent MRI imaging.
In animals with increased ICP the collection of CSF
carries the risk of parenchymal herniation. When sam-
pling is essential for the diagnosis and treatment of the
animal, pre-emptive use of mannitol (30 minutes prior to
CSF collection) and reduction of PaCO2 to 30 mmH
g (4kPa) by hyperventilation during the sampling period
may reduce the risk of herniation.
Electroencephalography
Electroencephalography records the spontaneous elec-
trical activity within the brain and may be performed 
in  animals  to  identify  areas  of  abnormal  electrical
activityresponsible for seizures. Performance of electro-
encephalography in conscious animals is difficult, as
muscle movement causes artefacts, which affect the diag-
nostic quality. Inhalational and intravenous anaesthetic
agents also alter the electrical activity within the brain in
a dose-dependent manner, thus limiting the amount of
useful information that can be obtained from electro-
encephalography in anaesthetized animals. A sedative
regimen  used  to  perform  electroencephalography  in
conscious animals has been described. This regimen was
reported to limit spontaneous movement in conscious
animals, while reducing the effects of deep sedation or
general anaesthesia on the recorded EEG. However, this
report describes the use of high doses of acepromazine, a
drug that may decrease seizure threshold. As discussed
above,  the  association  between  seizures  and  acepro-
mazine is still unclear and its use in animals with patho-
logical causes of seizure activity should be performed
cautiously. 
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